Rose Capital Advisors LLC Takes Position in Merck & Co., Inc. $MRK

Rose Capital Advisors LLC purchased a new position in Merck & Co., Inc. (NYSE:MRK) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,482 shares of the company’s stock, valued at approximately $576,000.

Several other institutional investors have also made changes to their positions in the stock. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $26,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $26,000. Graney & King LLC boosted its stake in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after buying an additional 200 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $31,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

MRK stock opened at $150.37 on Friday. The firm has a 50 day moving average of $134.64 and a two-hundred day moving average of $123.52. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $156.92. The company has a market capitalization of $370.99 billion, a price-to-earnings ratio of 120.30, a P/E/G ratio of 6.54 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the firm earned $2.13 EPS. Merck & Co., Inc.’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on MRK shares. BMO Capital Markets upped their price target on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, August 20th. Barclays lifted their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Weiss Ratings raised Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Finally, UBS Group raised their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $148.60.

Insider Buying and Selling

In related news, EVP Richard R. Deluca sold 11,699 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares of the company’s stock, valued at approximately $14,501,282.21. This trade represents a 9.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the sale, the executive vice president owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.